Copy
View email in your browser



StockWatchIndex
Adds TRACON Pharmaceuticals (TCON)
to its SWI Portfolio

Los Angeles, March 29, 2016. StockWatchIndex has added TRACON Pharmaceuticals (TCON:NASDAQGM) to its SWI Portfolio. TRACON Pharmaceuticals, Inc., is a clinical stage biopharmaceutical company that focuses on the development and commercialization of novel targeted therapeutics for cancer, wet age-related macular degeneration, and fibrotic diseases. TCON has several products in different advanced stages of clinical trials and has recently presented at the ROTH Capital 28th Annual Conference.  

        Click Here for Audio Webcast
   

Its lead product candidate is TRC105, which is in Phase II clinical trials for oncology indications, including soft tissue sarcoma, renal cell carcinoma, glioblastoma, and hepatocellular carcinoma. The companyÂ’'s other product candidates comprise TRC205, an endoglin antibody that is in preclinical stage for the treatment of fibrotic diseases; and TRC102, a small molecule, which is in clinical development for the treatment of lung cancer and glioblastoma. TRACON Pharmaceuticals, Inc. has collaboration agreements with National Cancer Institute and Santen.

        Click Here for latest Press Release


  
The company was formerly known as Lexington Pharmaceuticals, Inc. and changed its name to TRACON Pharmaceuticals, Inc. in March 2005. TRACON Pharmaceuticals, Inc. was founded in 2004 and is headquartered in San Diego, California. 



Rainer Poertner - Chief Analyst    

Please visit our sites www.stockwatchindex.com and  www.swiresearch.com. We would appreciate f you could
pass our newsletter on to your friends and colleagues. We always appreciate your feedback and comments
.

StockWatchIndex (SWI) is not a registered investment adviser and the information  provided herein or any other SWI publication is not to be construed as personal financial advice, or a solicitation to buy or sell stock. SWI makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in the publications for its Stock Watch List or on its web sites. Some information has been generated by publicly available sources, or what SWI deems to be reliable third party entities, but SWI does not guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or  warrant any results from use of the information. Readers are encouraged to consult their personal financial adviser before making any decisions to buy, sell or hold any securities mentioned herein. StockWatchIndex is not responsible for any error, mistake or shortcoming that may be occasioned at the time of publishing of the information in its Stock Watch List or on its web sites. No liability is accepted by StockWatchIndex whatsoever for any direct, indirect or consequential loss arising from the use of the information. StockWatchIndex expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information provided. SWI has acquired stock positions of the covered stock for its SWI Portfolio, has not been compensated by any of the companies it holds in its Portfolio and is not intending to trade any off these stocks in the short term.  The included information is subject to change without notice. Please visit http://www.stockwatchindex.com/about for a full text of our Disclaimer, Privacy policy and Terms of Use.
Copyright © 2016 DynamicMarketConcepts, All rights reserved.


unsubscribe from this list    update subscription preferences 

Email Marketing Powered by Mailchimp